Biotin-Linker-Label Epitope (BLL Epitope)

The Biotin-Linker-Label Epitope is a synthetic molecular construct designed to function as a bridge in adapter-mediated immunotherapy, most notably in universal Chimeric Antigen Receptor (CAR) T-cell platforms such as the AdCAR system. This technology decouples the antigen-recognition domain from the T-cell signaling domain by using a universal CAR-T cell that targets a specific synthetic tag—the biotinylated epitope—rather than a tumor-associated antigen directly (Urbanska et al., 2012). The target typically consists of a biotin moiety attached via a chemical linker to a label or an antigen-binding molecule, such as a monoclonal antibody. When the biotinylated antibody binds to a tumor cell, it presents the Biotin-Linker-Label Epitope on the cell surface, which is then recognized and bound by anti-biotin CAR-T cells, leading to localized T-cell activation and tumor lysis (Lohmueller et al., 2017). This modular approach offers significant therapeutic advantages, including the ability to target multiple different antigens simultaneously or sequentially by simply changing the biotinylated adapter administered to the patient. Furthermore, it provides a safety switch, as the CAR-T cell activity can be modulated or terminated by controlling the dosage or cessation of the adapter molecule (Kruse et al., 2016). The chemical linker is a critical component of the epitope, as it provides the necessary spatial orientation and flexibility for optimal immunological synapse formation between the effector T cell and the target cancer cell. While primarily used in oncology for treating B-cell malignancies and solid tumors, this synthetic target system is also being explored for pre-targeted imaging and other precision medicine applications (Miltenyi Biotec, 2023).

Other names

Biotinylated adapterBiotin-tagAnti-biotin CAR targetBiotin-linker-tag constructBiotinylated ligandSynthetic biotin epitope

The target acts as a molecular bridge in adapter-mediated immunotherapy; a biotinylated adapter (antibody) binds to a tumor-associated antigen, while the anti-biotin CAR-T cell recognizes the Biotin-Linker-Label Epitope on the adapter, triggering CAR signaling and cytotoxic tumor cell lysis.